Safety of long-acting beta-agonists.

Beta2-adrenoceptor agonists have been used as bronchodilators in the management of bronchial asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that beta2adrenoceptor agonist use may increase morbidity and mortality1. The long term beta-agonists, salmeterol and formeterol were introduced at the time of heightened concern about safety of beta2 agonist drugs. There have been occasional reports of deterioration in asthma control, and even respiratory arrest, following the commencement of a long-acting beta-agonist2-8.